Exelixis News

Former Pfizer Inc. executive Corey Goodman and two others - including the chairman of Alameda's InSite Vision - will join the board of Mirna Therapeutics Inc.

However hard the market slams a stock, there's always the chance it'll come bouncing right back.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, stem-cell technology specialist Cytori Therapeutics has earned a respected four-star ranking .

Exelixis Reports Encouraging Phase 1 Data For The PI3K Inhibitor Xl147 In Combination With Erlotinib At The AACR-NCI-EORTC Conference Main Category: Cancer / Oncology Also Included In: Clinical Trials / Drug Trials Article Date: 19 Nov 2009 - 23:00 PST Exelixis, Inc.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/17/09, DARA BioSciences, Inc.

Were it not for the downtime and the beer, you wouldn't be reading this story right now.

A fair amount of uncertainty continues to surround the healthcare sector as Congress debates how it can improve the existing system in the U.S. , but that has not prevented a number of stocks in the space from storming up the charts.

Nov 17, 2009 - Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 in combination with paclitaxel and carboplatin in patients with advanced solid tumors.

Exelixis, Inc. announced today that Frank Karbe, the company's executive vice president and chief financial officer, will present at Lazard's 6th Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York.

Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis . The 19% overnight gain has certainly gotten my attention .

Exelixis, Inc. announced today that thirteen abstracts related to the companya TMs development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston.

Exelixis and Bristol-Myers Squibb achieved positive Phase II data showing that XL184 demonstrated activity in patients with glioblastoma multiforme , the most common and aggressive form of brain cancer.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

LAKE FOREST, Ill.-- --Green Courte Partners, LLC, a Chicago-based private equity real estate investment firm, today announced that one of its affiliates --Notice is hereby given that Glancy Binkow & Goldberg LLP has filed a class action lawsuit in the United States District Court for the Northern District of California... NEWPORT BEACH, Calif.-- ...

Companies mentioned in this article: Exelixis, Inc. SOUTH SAN FRANCISCO, Calif. & NEW YORK -- -- Exelixis, Inc.

Frank Karbe, executive vice president and chief financial officer of Exelixis, reflects on some of the financial, regulatory, and intellectual property challenges facing the biopharma industry and shares his thoughts on what emerging leaders will need to do to address them.

Third quarter production volumes averaged 437 Mmcfe per day, a 13% increase over the pr... SOUTH SAN FRANCISCO, Calif.-- --Exelixis, Inc.

Bay Area biotech entrepreneur Corey Goodman joined the board of privately held, venture-backed NeuroTherapeutics Pharma Inc.

Our analysts have issued free ratings reports on the following six companies: ATP Oil & Gas Corp.